UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. BMID 9809 US

Total Pages in this Submission 53

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

 Tr in

ention entitled: ENZYME/TAG	BINDING AND DETECTION SYSTEM	
d invented by:	ncis Edward; BALGOBIN, Neil Gwyn; and McCARTHY, Robert Crane	
DWOLEI, FIAI	icis Davim sy	
CONTINUATI	ON APPLICATION, check appropriate box and supply the requisite information:	
a CONTINUATI	- O-minustion in-part (CIP) of prior application No	
/hich is a: Continuatio	Gardinuction in part (CIP) of prior application No.:	
/hich is a: Continuatio	n 🔲 Divisional 🗀 Continuation-in-part (CIP) of prior application No.:	
nclosed are:	Application Elements	
1. 🛭 Filing	fee as calculated and transmitted as described below	
2. ⊠ Spec	ification having 30 pages and including the following:	
. [7]	Descriptive Title of the Invention	
	Cross References to Related Applications (if applicable)	
b. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)	
	Reference to Microfiche Appendix (if applicable)	
e. 🗵	Background of the Invention	
f. 🗵	Brief Summary of the Invention	
g. 🗆	Brief Description of the Drawings (if drawings filed)	
h. 🗵	Detailed Description	
i. 🗵	Claim(s) as Classified Below	
i 🔯	Abstract of the Disclosure	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. BMID 9809 US

Total Pages in this Submission 53

	l
Application Elements (Continued)	
3. □ Drawing(s) (when necessary as prescribed by 35 USC 113)	
a. Formal Number of Sheets	
b.	
4. 🗵 Oath or Declaration	
a. 🗵 Newly executed (original or copy) 🔲 Unexecuted	
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)	
c. 🗵 With Power of Attorney 🔲 Without Power of Attorney	
d. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).	
5. Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	∍r 'Y
6. Computer Program in Microfiche (Appendix)	
7. 🗵 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)	
a. ⊠ Paper Copy	
b. 🗵 Computer Readable Copy (identical to computer copy)	
c. 🗵 Statement Verifying Identical Paper and Computer Readable Copy	
Accompanying Application Parts	
8. Assignment Papers (cover sheet & document(s))	
9. 37 CFR 3.73(B) Statement (when there is an assignee)	
10. 🗀 English Translation Document (if applicable)	
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations	
12. 🔲 Preliminary Amendment	
13. ⊠ Acknowledgment postcard	
14. 🗵 Certificate of Mailing	
☐ First Class ☑ Express Mail (Specify Label No.): EL 841984005 US	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. BMID 9809 US

Total Pages in this Submission

	Accompanying Application Parts (Continued)
15. 🔲 Ce	ertified Copy of Priority Document(s) (if foreign priority is claimed)
16. 🗆 A	dditional Enclosures (please identify below):
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
47.	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that this patent application disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in pub
-	Warning
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country of under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specified i
E-auto	was uninternesses

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BMID 9809 US

Total Pages in this Submission 53

Fee Calculation and Transmittal

CLAIMS AS FILED

			CLAINS	A0 1 1222		
		#Filed	#Allowed	#Extra	Rate	Fee
44 44	For	<u> </u>	- 20 =	0	x \$18.00	
otal C	Claims	10		0	x \$80.00	
	Claims	3	- 3 =			
ultip	le Dependent C	laims (chec	k if applicable)		BASIC FEE	
					D /10/0	
OTH	ER FEE (specif	y purpose)				
					TOTAL FILING FEE	
Date	☒ Charge t☒ Credit ar☒ Charge☐ Chargepursuan	the amount only overpaym any additional the issue fee at to 37 C.F.F.	ent. al filing fees requir e set in 37 C.F.R. 1	od under 37	C.F.R. 1.16 and 1.17. railing of the Notice of Allowance, Signature Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostics Corporation 9115 Hague Road, Bldg. D P.O. Box 50457 Indianapolis, IN 46250-0457 Telephone No.: (317) 521-3375	
cc:					Facsimile No.: (317) 521-2883	
1						

\$0.00

\$0.00

\$0.00

\$710.00

\$0.00

\$710.00

i: 1				
	AILING BY "EXPRESS rancis Edward	MAIL" (37 CFR 1.10)	Docket No. BMID9809US	
Serial No.	Filing Date	Examiner	Group Art Unit	
To Be Assigned	July 10, 2001	To Be Assigned	To Be Assigned	
Invention: ENZYME/TAC	BINDING AND DETECTIO	N SYSTEM		
I hereby certify that this		U.S. Utility Patent Application (Identify type of correspondence)		
is being deposited with	the United States Postal Serv	vice "Express Mail Post Office to	Addressee" service under	
		tant Commissioner for Patents, W		
July 10, 2				
the state of the s		Rose Edwar	ds	
8-2 5-2		(Typed or Printed Name of Person Mo		
- 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10		Paze Edi	vards	
		(Signature of Person Mailing C	Correspondence)	
State		EL 841984005	S US	
		("Express Mail" Mailing Lo	abel Number)	
Arms See -4				

Note: Each paper must have its own certificate of mailing.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dwulet et al.

Application No.: unknown

Group No.: unknown

Filed: July 10, 2001

Examiner: unknown

For: ENZYME/TAG BINDING AND DETECTION SYSTEM

Box SN Assistant Commissioner for Patents Washington, D.C. 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Dear Sir:

The undersigned hereby states that the content of the Sequence Listing filed herewith (4 pages, numbered 1 to 4) and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same and contain no new matter. Also enclosed is a Checker 3.0 Verification Summary Report demonstrating that the Sequence Listing complies with the applicable rules.

Respectfully submitted,

Date: July 10, 2001

Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostics Corporation 9115 Hague Road, Bldg. D

P.O. Box 50457

Indianapolis, IN 46250-0457 Telephone: (317) 521-3104